Chronic Kidney Disease
WASHINGTON — Results from the phase 3 OLYMPUS trial presented here show the investigational hypoxia-inducible factor prolyl hydroxylase inhibitor drug roxadustat significantly increased hemoglobin levels in patients with anemia and chronic kidney disease compared to those treated with placebo.
There is no commercial support for this activity.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.